Scinovex
article Open AccessTop 1% cited

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

Annals of the Rheumatic Diseases · 2008 · Vol. 67(11) · pp. 1516–1523
Paul EmeryEdward KeystoneHans‐Peter TonyAlain CantagrelRonald van VollenhovenAntonio SánchezEmma AlecockJ. LeeJoel M. Kremer

Abstract

NCT00106522.

Rheumatoid Arthritis Research and TherapiesToxin Mechanisms and ImmunotoxinsAutoimmune and Inflammatory Disorders ResearchMedicineTocilizumabRheumatoid arthritisInternal medicineAdverse effectPlaceboGastroenterologyRashMethotrexateRefractory (planetary science)

MeSH terms

AdolescentAdultAgedAntibodies, MonoclonalArthritis, RheumatoidDose-Response Relationship, DrugDouble-Blind MethodDrug Therapy, CombinationFemaleHumansMaleMethotrexateMiddle AgedSeverity of Illness IndexTumor Necrosis Factor-alpha

Funding

  • Chugai Pharmaceutical
Citations
1,104
FWCI
59.13
field-weighted impact
References
62
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.